360o Virtual Tour360<sup>o</sup> Virtual Tour
Speak to Our Experts

High-quality, scalable, and customized enzymatic mRNA production. In vitro transcription (IVT) is the method of choice for producing long and stable RNA molecules such as mRNA, guide RNA, or long RNA.

Our offering

  • Customized mRNA synthesis using scalable and standardized processes capable of delivering milligram to multi-gram quantities with lengths ranging from a few hundred nucleotides to kilobases
  • Process development for customized manufacturing of in vitro transcribed RNA, including reagent proteins for IVT mRNA synthesis and capping
  • Synthesis and customized production of modified bases and bio-reagents
  • Reporter RNAs tailored to aid your expression studies. These are akin to fully processed mature mRNA, which ensures improved stability and performance. Our high-quality mRNA transcripts are ideal for functional analysis, therapeutics, diagnostics, and vaccine production.

Features of IVT mRNA synthesis service

  • RNA transcripts from plasmids, PCR products and cDNA
  • Conventional and Self-amplifying RNA (SAM)
  • Flexibility to choose transcriptional promoter (T7 or SP6)
  • Normal, unmodified mRNA synthesis
  • Use of modified bases in mRNA transcripts (Pseudo UTP etc.)
  • Several strategies for 5’ capping including but not limited to;
    • Co-translational capping with Anti Reverse Cap Analog (ARCA)
    • Post-translational Vaccinia capping system
  • Options to choose from Cap0 and Cap1
  • Template derived poly-A tail or enzymatic incorporation into the IVT mRNA
  • Well-characterized mRNA synthesis and purification processes
  • mRNA synthesis and purification under RNase free environment
  • Process optimization for scales up to gram quantities
  • Validated source for critical reagents
  • Standard and custom QC assays (both qualitative and quantitative)
  • Batch to batch consistency of the IVT mRNA
  • Endotoxin-free process
  • Delivered as solution or lyophilized

Additional services

  • Sequence design and gene synthesis (outsourced)
  • Customized sub-cloning
  • DNA purification and quantification
  • DNA sequencing verification
  • IVT template generation
  • Residual template DNA analysis
  • IVT reaction followed by purification
    • With or without DNase I treatment
    • Lithium chloride precipitation
    • Column based purification
  • RNA quantification
  • Purity check by Bioanalyzer, SE-HPLC
  • RNA length confirmation (Bioanalyzer, agarose gel electrophoresis)
  • RNA sequence confirmation
  • Endotoxin measurement
  • Bioburden testing of the final IVT mRNA sample
  • Qualitative and quantitative measurement of capping enzyme activity and efficiency
  • Expression and purification of IVT mRNA and capping enzymes
  • Buffer exchange for custom mRNA formulation
  • Conjugation and labeling of mRNA
  • Synthesis of guide RNAs by IVT and designing custom mRNAs for genome engineering
  • RNA structural studies

mRNA Pharmacology

  • Formulation development for mRNA delivery
  • Optimization of mRNA translation and stability
  • Immunogenicity testing

Aurigene Pharmaceutical Services is

one of the leading contract research organization (CRO)

provides the best contract research manufacturing


There are several chromatography techniques to purify mRNA namely Ion exchange, polydT, Silica-based columns, Gel filtration, Reverse Phase, commercially available RNA clean-up kits, magnetic beads etc. as well as simple RNA precipitation methods using chemicals like LiCl.

By diluting in nuclease-free water or mild buffers like Tris-EDTA etc.

There are several plasmids available commercially for in vitro transcription. Several factors influence the choice of vectors or plasmids like cost, design, application, expression system, sequence of the 5’ and 3’ UTR, length of the polyA tail, template generation method, size of the plasmid and mRNA insert, IP etc.

Yield of mRNA generally depends on several factors related to the IVT process and the desired mRNA molecule. Process development is generally required for optimization of the IVT mRNA yield using different IVT template plasmids, promoter sequence, optimized UTRs, gene sequence optimization, reaction temperature and time, template purity, length of polyA, purification method etc.

There is no direct relationship between the level of mRNA and proteins. Studies estimating transcripts and proteins revealed the importance of several other processes and factors beyond transcript concentration that contribute to establishing the expression level of a protein. Aspects such as mRNA concentration, half- life, secondary structure, translation rates, mRNA and UTR sequences, internal ribosome entry sites (IRES), translation rate modulation, non-coding RNAs, ribosome abundance, protein half-life, internal cellular conditions, protein processing and degradation, protein synthesis delay, protein transport etc. influence the correlation between mRNA and protein levels in a cell. Thus, the direct comparison between protein and mRNA abundances from the same location or from the same cell type may not be appropriate.

Several methods such Capillary electrophoresis, Agarose and Polyacrylamide gel electrophoresis, Analytical Size-exclusion chromatography, qRT-PCR, Dot Blot, Mass Spectrometry etc. are employed for quality analysis of in vitro transcribed mRNA.

Explained in question no. 5

Once mRNAs enter the cell, they are either translated to proteins, stored for later translation (translational repression), or degraded by endonucleolytic cleavage. All mRNAs are ultimately degraded at a defined rate as per the cellular needs and mRNA half-life.

Quite a few strategies alone or in combination such as plasmid template purity, capping, polyA tail length, ORF sequence optimization, UTR sequences, use of base analogs, purification strategy, mRNA quality and removal of contaminants are generally considered to improve stability, export and translation of IVT mRNA.

Exogenous or IVT mRNA is inherently immune-stimulatory, as it is recognized by a variety of cell surface, endosomal and cytosolic innate immune receptors. It is potentially advantageous for vaccination because in some cases it may provide adjuvant activity to drive dendritic cell (DC) maturation and thus elicit robust T and B cell immune responses. Enzymatically synthesized mRNA preparations contain double-stranded RNA (dsRNA) contaminants as aberrant products of the IVT reaction. dsRNA and sometime structural elements of ssRNA is a potent pathogen-associated molecular pattern (PAMP) that is sensed by pattern recognition receptors such as Toll-like receptor resulting in robust type I interferon (INF) production when delivered exogenously. INF up-regulates protein kinases and synthetases, leading to the inhibition of translation and the degradation of cellular and ribosomal RNA. Besides translation products of the IVT mRNA are also recognized as foreign and elicit immune responses, a strategy used in vaccines.

Efficient in vivo mRNA delivery is of therapeutic significance. Exogenous mRNA must cross the barrier of the lipid membrane in order to reach the cytoplasm to be translated to functional protein. mRNA uptake mechanisms seem to be cell type dependent, and the physicochemical properties of the mRNA complexes can profoundly influence cellular delivery and organ distribution. There are two basic approaches for the delivery of mRNA vaccines. First, loading of mRNA into DCs ex vivo, followed by re-infusion of the transfected cells; and second, direct parenteral injection of mRNA with or without a carrier like protamine liposome, cationic polymers, nanoparticles etc.

Genome engineering, gene silencing, genetic reprogramming are some of the preclinical applications of IVT mRNA e.g. CRISPR Cas9. Use of IVT mRNA in clinical applications like are cancer immunotherapy, vaccines against infectious diseases, allergy tolerization, protein replacement therapies, regeneration therapies etc. are currently being explored as alternative immunotherapeutic.

Virtual Tour

Contact Us

5 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.